<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314782</url>
  </required_header>
  <id_info>
    <org_study_id>D4320C00020</org_study_id>
    <secondary_id>4054IL/0020</secondary_id>
    <nct_id>NCT00314782</nct_id>
  </id_info>
  <brief_title>Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC</brief_title>
  <official_title>A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in
      combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK)
      profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer
      (HRPC)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Part A: Cycle 1 ('Primary analysis' corresponding to data cut-off 5th March 2008)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD4054 (Zibotentan)</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Zibotentan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part B (placebo)</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part B (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Histological or cytological confirmation of prostate cancer

          -  Evidence of metastatic disease on CT scan, MRI, or bone scan

          -  Surgically or continuously medically castrated with LHRH analogue

          -  Progressive disease after most recent therapy

               -  Disease progression by CT/MRI

               -  Bone scan progression: appearance of 1 or more new lesions since last bone scan

               -  Rising PSA

          -  World health organization (WHO) performance status 0 to 2

          -  Life expectancy of 12 weeks or longer

        Exclusion Criteria:

          -  Use of anti-hormonal therapies (including ketoconazole, aminoglutethimide, finasteride
             and anti-androgen therapies) within 4 weeks of starting study treatment, except for
             bicalutamide and nilutamide which are excluded within 6 weeks of starting study
             treatment. Estramustine or estrogens, if taken, have to be stopped at least 4 weeks
             before starting treatment.

          -  Definite or suspected personal history or family history of adverse drug reactions, or
             hypersensitivity to drugs that are endothelin antagonist; history of severe
             hypersensitivity reactions to drugs formulated with polysorbate 80.

          -  Prior cytotoxic chemotherapy for metastatic prostate cancer

          -  Radiotherapy within 4 weeks before the start of study therapy

          -  Systemic radionuclide therapy (ie strontium chloride Sr89, 186Re-labeled HEDP, or
             153Sm-EDTMP pentasodium) within 12 weeks before entering study

          -  Use of potent CYP450 inhibitors (such as itraconazole, ritonavir, indinavir,
             erythromycin, troleandomycin, clarithromycin, diltiazem, verapamil) within 2 weeks
             before study entry.

          -  Use of potent CYP450 inducers (such as phenytoin, rifampicin, carbamazepine and
             phenobarbitone, St. John's Wort) within 2 weeks before study entry.

        NOTE: Dexamethasone is a known inducer of CYP2D6 and CYP3A4 but is not considered
        exclusionary for purposes of this study.

          -  New neurologic symptoms or signs consistent with acute or evolving spinal cord
             compression confirmed by magnetic resonance imaging (MRI) (except for those previously
             treated and have stable symptoms).

          -  History of past or current epilepsy, epilepsy syndrome, or other seizure disorder

          -  History of Migraine or chronic headache

          -  Symptomatic central nervous system (CNS) metastases

          -  Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L (1,5000/mm3)

          -  Platelet count &lt; 100 x 109/L (100,000/mm3)

          -  Serum bilirubin greater than the upper limit of normal (ULN)

          -  Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 1.5
             times the upper limit of normal (ULN)

          -  Creatinine clearance &lt;50 mL/min

          -  QT interval corrected for heart rate by the Barrett Formula (QTc) &gt; 470 msec at
             screening

          -  New York Heart Association (NYHA) class II-IV Heart Disease

          -  Myocardial infarction (heart attack) within past 3 months

          -  CTCAE grade ≥2 Peripheral Neuropathy

          -  Treatment with a non-approved or investigational drug within 30 days before study
             entry

          -  Evidence of any other significant clinical symptoms, abnormal laboratory findings or
             recent surgery that patients has not recovered from that make it undesirable for the
             patient to participate in the study in the opinion of the investigator(s)

          -  Involvement in the planning and conduct of the study

          -  Previous treatment in the present study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Emerging Oncology Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic hormone-refractory prostate cancer (HRPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

